glp-1 fda approved New Pill Foundayo (Orforglipron) Gets Approval for Obesity GLP-1 Injections for Medical Weight

174 Currently, Eli Lilly has initiated a Phase III development program to further investigate the efficacy and safety of orforglipron in treating obesity, overweight, and T2DM

The TRIUMPH-4 trial protocol provides the best reference for effective dosing : Weeks 1-4: 2 mg once weekly (starting dose) Weeks 5-8: 4 mg once weekly Weeks 9-12: 6 mg once weekly Weeks 13-16: 8 mg once weekly Week 17+: 9 mg or 12 mg once weekly (maintenance dose) The escalation happens every 4 weeks, which is slightly faster than many tirzepatide protocols

Richmond)

At Turkle & Associates and Phases Skin Care & Laser Center, weve helped countless patients restore their contours, improve skin tone, and enhance their natural beauty after significant weight loss